Ohr Pharmaceutical to Announce First Quarter 2017 Financial Results on February 14
NEW YORK, Feb. 13, 2017 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that it will report financial results for its first fiscal quarter ended December 31, 2016 before the market open on Tuesday, February 14, 2017. The Company will also hold a live investor conference call and webcast at 7:45am Eastern Time.
Conference Call & Webcast|
Tuesday, February 14 @ 7:45am Eastern Time|
Replays – Available through February 21, 2017|
About Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP) is an ophthalmology research and development company. The company's lead drug candidate, Squalamine lactate ophthalmic solution, 0.2% (also known as OHR-102), is currently being evaluated in combination with anti-VEGF injections in a clinical program for the treatment of the wet form of age-related macular degeneration. In addition, Ohr has a sustained release micro fabricated micro-particle ocular drug delivery platform. Additional information about the company may be found at www.ohrpharmaceutical.com.
Contact: Ohr Pharmaceutical Inc. Investor Relations 888-388-2327 firstname.lastname@example.org LifeSci Advisors, LLC Michael Wood 646-597-6983 email@example.com